Valeritas (NASDAQ:VLRX) issued its quarterly earnings data on Friday. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.07, MarketWatch Earnings reports. The firm had revenue of $6.93 million during the quarter. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 205.12%. Valeritas updated its FY 2018 guidance to EPS.
Shares of VLRX traded down $0.12 on Friday, reaching $1.08. 684,617 shares of the company’s stock traded hands, compared to its average volume of 355,958. The company has a current ratio of 4.03, a quick ratio of 3.42 and a debt-to-equity ratio of 13.66. The company has a market capitalization of $28.59 million, a price-to-earnings ratio of -0.13 and a beta of 2.58. Valeritas has a 52-week low of $0.78 and a 52-week high of $6.79.
Separately, Oppenheimer set a $4.00 price target on Valeritas and gave the company a “buy” rating in a research report on Tuesday, August 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Valeritas presently has a consensus rating of “Buy” and a consensus price target of $3.67.
Several institutional investors and hedge funds have recently modified their holdings of VLRX. Essex Investment Management Co. LLC purchased a new stake in shares of Valeritas during the second quarter valued at approximately $448,000. Bainco International Investors purchased a new stake in shares of Valeritas during the second quarter valued at approximately $228,000. Finally, C WorldWide Group Holding A S increased its position in shares of Valeritas by 28.0% during the second quarter. C WorldWide Group Holding A S now owns 316,194 shares of the company’s stock valued at $424,000 after acquiring an additional 69,216 shares during the last quarter. 7.38% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/11/10/valeritas-vlrx-releases-quarterly-earnings-results-beats-expectations-by-0-07-eps.html.
Valeritas Company Profile
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Recommended Story: Hedge Funds – How They Work For Investors
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.